Revenue (Annual)

Revenue: The sum of all revenue fields included for a company's operating activities.

Jazz Pharmaceuticals PLC (JAZZ) had Revenue of $4.07B for the most recently reported fiscal year, ending 2024-12-31.

Quarterly Annual

Figures for fiscal year ending 2024-12-31

Income Statement Financials
Revenue	$4.07B
Net Income	$570.88M
Cost of Goods Sold	$445.71M
Gross Profit	$3.62B
Operating Expenses	$3.35B
Operating Income	$716.63M
Non-Operating Income/Expense	$-246.28M
Pre-Tax Income	$470.35M
Normalized Pre-Tax Income	$470.35M
Income after Taxes	$561.78M
Income from Continuous Operations	$560.12M
Consolidated Net Income/Loss	$560.12M
Normalized Income after Taxes	$561.78M
EBIT	$716.63M
EBITDA	$1.38B
Weighted-Average Shares Outstanding (Basic)	61.84M
Weighted-Average Shares Outstanding (Diluted)	66.01M
Earnings per Share (EPS) (Basic)	$9.06
Earnings per Share (EPS) (Diluted)	$8.65
Balance Sheet Financials
Current Assets	$4.63B
Property, Plant, and Equipment	$173.41M
Long-Term Assets	$7.38B
Total Assets	$12.01B
Current Liabilities	$1.04B
Long-Term Debt	$6.08B
Long-Term Liabilities	$6.88B
Total Liabilities	$7.92B
Common Equity	$4.09B
Tangible Shareholders Equity	$-2.38B
Shareholders Equity	$4.09B
Common Shares Outstanding	60.63M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$1.40B
Cash Flow from Investing Activities	$-508.19M
Cash Flow from Financial Activities	$20.52M
Beginning Cash	$1.51B
End Cash	$2.41B
Increase/Decrease in Cash	$906.55M
Stock-Based Compensation	$248.04M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	4.46
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.60
Debt to Equity Ratio	1.49
Gross Margin	89.05%
Operating Margin	17.61%
EBIT Margin	17.61%
EBITDA Margin	33.83%
Pre-Tax Profit Margin	11.56%
Profit Margin	14.03%
Free Cash Flow	$1.36B
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.34
Inventory Turnover	0.93
Receiveable Turnover	5.68
Days Sales in Receivables	64.30
Return on Equity	13.68%
Return on Tangible Equity	-23.55%
Return on Assets	4.66%
Return on Investments	5.51%
Book Value Per Share	$67.52
Free Cash Flow per Share	$20.57
Operating Cash Flow per Share	$21.15

Data from Zacks Investment Research, Inc.